ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

INTS Intesity Therapeutics Inc

4.97
0.00 (0.00%)
02 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Intesity Therapeutics Inc INTS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 4.97 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.97
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/5/202415:00EDGAR2Form 8-K - Current report
15/5/202407:01PRNUSIntensity Therapeutics, Inc. Announces the Appointment of..
10/5/202415:00EDGAR2Form 8-K - Current report
10/5/202407:01PRNUSIntensity Therapeutics, Inc. and The Swiss Group for..
09/5/202415:13EDGAR2Form 8-K - Current report
09/5/202415:08PRNUSIntensity Therapeutics Reports First Quarter 2024 Financial..
09/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/4/202407:01PRNUSIntensity Therapeutics to Participate in the LD Micro..
26/3/202407:01GLOBEPortage Biotech Completes Monetization of Intensity..
14/3/202415:09PRNUSIntensity Therapeutics Reports Full Year 2023 Financial..
14/3/202407:00PRNUSIntensity Therapeutics to Participate in the 36th Annual..
07/3/202417:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202407:01PRNUSIntensity Therapeutics to Present at the 2024 BIO CEO &..
07/2/202415:15EDGAR2Form 8-K - Current report
03/1/202407:01PRNUSIntensity Therapeutics Provides Business Update Reflecting..
12/12/202307:02EDGAR2Form 8-K - Current report
12/12/202307:01PRNUSIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief..
08/12/202307:30PRNUSIntensity Therapeutics Presents Positive INT230-6 Data in..
01/12/202307:01PRNUSIntensity Therapeutics Selected for Spotlight Oral..
13/11/202311:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202307:02EDGAR2Form 8-K - Current report
13/11/202307:01PRNUSIntensity Therapeutics Reports Third Quarter Financial..
02/11/202306:01PRNUSIntensity Therapeutics Presents Positive INT230-6 Data in..
07/9/202307:01PRNUSIntensity Therapeutics Receives Orphan Drug Designation for..
05/9/202307:01PRNUSIntensity Therapeutics to Present at the H.C. Wainwright..
14/8/202306:01PRNUSIntensity Therapeutics Reports Second Quarter Financial..
07/8/202306:01PRNUSIntensity Therapeutics to Announce Financial Results for the..
10/7/202307:00PRNUSIntensity Therapeutics, Inc. Announces the Closing and Full..
05/7/202315:15PRNUSIntensity Therapeutics, Inc. Announces Closing of Upsized..
29/6/202319:00PRNUSIntensity Therapeutics, Inc. Announces Pricing of Upsized..
06/6/202306:35PRNUSIntensity Therapeutics Reports INT230-6 Can Cause Immune..

Su Consulta Reciente

Delayed Upgrade Clock